In more detail regarding cardiometabolic comorbidities, patients with AF and CHIP mutations present a higher prevalence of hypertension, while TET2 deficiency, due to TET2 somatic mutations identified in human tissues via deep-targeted sequencing, has been demonstrated in population-based studies to be an aggravating factor for cardiac dysfunction, NLRP3 inflammasome activation, and sodium retention, effects that can be considered potential therapeutic targets in AF patients [58,115]. The gene discussed is TET2; the disease is Hypertension.